Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC-503 in secondary (AA) amyloidosis
NCT00035334Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in AA amyloidosis comparing NC-503 with Placebo (2 arms). Primary endpoint: Composite assessment of clinical improvement/worsening of renal and gastrointestinal functions at 24 months. Started Oct 2001; status: completed.
02
Drugs
eprodisate
03
Conditions
AA amyloidosis
Beyond the preview
Go deeper on NCT00035334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035334.